TG THERAPEUTICS, INC. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
TG Therapeutics reported Q2 2026 total revenue of $240.3M (BRIUMVI U.S. net product revenue $227.7M, up 64% YoY) and raised full-year 2026 guidance to approximately $950M total global revenue and $890–905M BRIUMVI U.S. net revenue, signaling strong commercial traction. The company also announced positive Phase 3 ENHANCE results supporting a simplified one-dose initiation regimen, Phase 1 subcutaneous BRIUMVI data (>60% bioavailability vs. IV), and advancement into myasthenia gravis and schizophrenia indications. Cash position stands at $612.3M as of June 30, 2026.
Why this rating
Strong revenue beat and upward guidance (28% of market cap in annualized run rate) materially de-risks commercial execution; pipeline expansion into new indications is material optionality for ~$2.5B company.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.